Andrea Cercek MD

Oncology•New York, NY

Instructor, Medicine, Weill Cornell Medical College

Request appointment

160 East 53rd StreetNew York, NY 10022
Book by Phone+1(570) 669-8649

Overview of Dr. Cercek

Dr. Andrea Cercek is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from New York Medical College and has been in practice 22 years. She is one of 537 doctors at Memorial Sloan Kettering Cancer Center and one of 68 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 100 publications and over 500 citings.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2006 - 2028
CT State Medical License 2024 - 2027
NJ State Medical License 2020 - 2027
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017

Clinical Trials

Clinical and Translational Study of STA-9090
COMPLETED
PHASE2
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
COMPLETED
PHASE1
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Start of enrollment: 2013 Sep 05
COMPLETED
PHASE1

Publications & Presentations

PubMed

Universal Germline Genetic Testing after a Diagnosis of Cancer.
Zsofia K Stadler, Anna Maio, Aliya Khurram, Kanika Arora, Chaitanya Bandlamudi
Cancer Discovery. 2026-10-08
Genomic predictors of pathologic response to hepatic artery infusion pump chemotherapy in colorectal liver metastases.
Naaz F Nasar, Joanne F Chou, Jashodeep Datta, Maya T Evenhaim, Mithat Gonen
HPB. 2026-10-01
ASO Visual Abstract: Investigating Age-Related Differences in Survival Outcomes and Mutation Status in Patients with Intrahepatic Cholangiocarcinoma.
Misha Armstrong, Hannah Kalvin, Mithat Gönen, Ghassan Abou-Alfa, Vinod P Balachandran
Annals of Surgical Oncology. 2026-10-01

Journal Articles

Locoregional Therapy plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—Reply
Andrea Cercek, MD, JAMA Oncology
Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits
Jinru Shia, Garrett M Nash, Philip B Paty, Andrea Cercek, Campbell S Roxburgh, Annals of Surgical Oncology
Pelvic MRI After Induction Chemotherapy and Before Long-Course Chemoradiation Therapy for Rectal Cancer: What Are the Imaging Findings?
Andrea Cercek, Leonard Saltz, Marc J Gollub, Patricio Lynn, Martin R Weiser, European Radiology

Lectures

Gastrointestinal (Colorectal) Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Prevalence of germline genetic alterations in colorectal cancer patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Locoregional Therapy plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—ReplyApril 2020

Press Mentions

Nearly Half of Colorectal Cancers Now Occur in Younger Patients, Study ShowsMarch 2nd, 2026
The Rise of Early-Onset Cancers: Leading Hypotheses and Emerging OpportunitiesSeptember 16th, 2025
Experimental Drug Cures All Patients of Cancer in Clinical TrialAugust 3rd, 2025

Grant Support

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerSLOAN-KETTERING INST CAN RESEARCH2024–2029
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancerSLOAN-KETTERING INST CAN RESEARCH2022–2027
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025